Update - SCENESSE in vitiligo
Filed with ASX · · 3 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL implements strategic reorganisation to refocus on U.S. markets
- CLINUVEL strategic reorganisation to refocus on U.S. markets
- SCENESSE® approved for EPP in Canada
- CLINUVEL publicly files 20-F to U.S. SEC
- CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
Later from Clinuvel Pharmaceuticals
- Commercial update on vitiligo
- A decade of profitability provides U.S. expansion foundation
- Appendix 4E and Annual Report to Shareholders 2026
- CLINUVEL considers Nasdaq listing, ASX delisting
- A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals